Reply to the letter from Kataoka et al.
作者信息
Mohanty Sanghamitra, Natale Andrea
机构信息
Division of Electrophysiology, Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, USA.
Department of interventional electrophysiology, Interventional Electrophysiology, Scripps Clinic, San Diego, California, USA.
出版信息
J Cardiovasc Electrophysiol. 2024 Sep;35(9):1901-1902. doi: 10.1111/jce.16368. Epub 2024 Jul 14.
PMID:39004812
Abstract
摘要
相似文献
1
Reply to the letter from Kataoka et al.
J Cardiovasc Electrophysiol. 2024 Sep;35(9):1901-1902. doi: 10.1111/jce.16368. Epub 2024 Jul 14.
2
Reply to Letter by Kataoka, et al. Regarding Article, "Correlation of Serum Laminin Levels with Cardiac Function and In-Hospital Prognosis in Patients with Atrial Fibrillation".
Int Heart J. 2023;64(5):964. doi: 10.1536/ihj.23-321.
3
Letter by Kataoka, et al. Regarding Article, "Short P-Wave Duration Is Associated with Incident Atrial Fibrillation".
Int Heart J. 2023 Mar 31;64(2):326. doi: 10.1536/ihj.22-424. Epub 2023 Mar 15.
4
Letter by Kataoka, et al. Regarding Article, "Correlation of Serum Laminin Levels with Cardiac Function and In-Hospital Prognosis in Patients with Atrial Fibrillation".
Int Heart J. 2023;64(5):963. doi: 10.1536/ihj.23-229.
5
Letter by Kataoka, et al. Regarding Article, "Investigation of Stroke Risk Factors and Prognostic Indicators in NVAF Patients with Low CHADS-VASc Scores".
Int Heart J. 2024;65(3):591. doi: 10.1536/ihj.24-019.
6
Response to the Letter by Kataoka, et al. Regarding the Article, "Investigation of Stroke Risk Factors and Prognostic Indicators in NVAF Patients with Low CHADS-VASc Scores".
Int Heart J. 2024;65(3):592. doi: 10.1536/ihj.24-174.
7
Anticoagulation for atrial fibrillation in patients with active cancer: Reply to the 'Letter to the Editor' from Dr. Sorigue et al.
Int J Cardiol. 2019 Apr 1;280:97. doi: 10.1016/j.ijcard.2019.01.006.
8
Reply to Letter by Kataoka, et al. Regarding Article, "Evaluation of Plasma Xanthine Oxidoreductase (XOR) Activity in Patients with Cardiopulmonary Arrest".
Int Heart J. 2024;65(1):166-167. doi: 10.1536/ihj.23-564.
9
Reply to Kataoka, N.; Imamura, T. How to Improve Clinical Outcomes in Patients with Tachycardia-Induced Cardiomyopathy. Comment on "Katz et al. Long-Term Outcomes of Tachycardia-Induced Cardiomyopathy Compared with Idiopathic Dilated Cardiomyopathy. 2023, , 1412".
J Clin Med. 2023 Sep 8;12(18):5849. doi: 10.3390/jcm12185849.
10
Reply to Letter From Roca et al.-Frailty and Anticoagulation Prescription Rate for Atrial Fibrillation in the Elderly.
Can J Cardiol. 2016 Feb;32(2):270.e11. doi: 10.1016/j.cjca.2015.09.013. Epub 2015 Sep 26.
引用本文的文献
1
Cardioembolic stroke in cardiac amyloidosis is a formidable challenge.
J Interv Card Electrophysiol. 2024 Oct;67(7):1477-1478. doi: 10.1007/s10840-024-01865-0. Epub 2024 Jul 4.
Zotero 插件